DanTVoglMDMSCE

Hematologic Oncology

Assistant Professor of Medicine

Dr. Vogl is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
3400 Civic Center Blvd
Philadelphia, PA 19104
Phone+1 215-615-6508

Fax+1 215-615-5887

University of Pennsylvania Perelman School of MedicineMSCE, Clinical Trials Methodology, 2009
University of Pennsylvania Health SystemFellowship, Hematology and Medical Oncology, 2003 - 2006
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2000 - 2003
Weill Cornell MedicineClass of 2000

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

PubMed

42 citations
Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma
Dan T. Vogl, Tao Wang, Waleska S. Pérez, Edward A. Stadtmauer, Daniel F. Heitjan
Biology of Blood and Marrow Transplantation. 2011-12-01
26 citations
Trimming the fat: obesity and hematopoietic cell transplantation
Brendan M. Weiss, Dan T. Vogl, Nathan A. Berger, Edward A. Stadtmauer, Hillard M. Lazarus
Bone Marrow Transplantation. 2013-09-01
57 citations
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
Guido Ghilardi, Joseph A Fraietta, James N Gerson, Vivianna M Van Deerlin, Jennifer J D Morrissette
Nature Medicine. 2024-04-01

Journal Articles

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-Exposure SARS-CoV-2 Prophylaxis Among Health Care Workers
Matthew C Hyman, Ian Frank, Scott E Hensley, Saar Gill, Dan T Vogl, Ivan Maillard, Daria V Babushok, Alexander C Huang, Sunita D Nasta, Jennifer C Walsh, Michael C Mil..., JAMA Internal Medicine

Abstracts/Posters

Selinexor-Containing Regimens for the Treatment of Patients with Multiple Myeloma Refractory to Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
Dan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Influence of Cytogenetics in Patients with Relapsed Refractory Multiple Myeloma Treated with Oral Selinexor and Dexamethasone: A Post-Hoc Analysis of the STORM Study
Dan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma
Dan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...
Dan T. Vogl, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Re...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Karyopharm’s Selinexor Combination for Multiple Myeloma Unlikely to See Second-Line Use Despite Likely FDA ApprovalDecember 18th, 2020
$Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual Meeting$
Phase 2b STORM Data Evaluating Selinexor in Patients with Penta-Refractory Multiple Myeloma Presented at the Society of Hematologic Oncology 2018 Annual MeetingSeptember 14th, 2018
Novel Agents, Combos Excite in Multiple MyelomaNovember 28th, 2017
Join now to see all